Clinical significance
Somatic alterations in PPP2R1B have been identified in colorectal and lung cancer tumors and cell lines, [8] with evidence that these alterations affect protein function, supporting a role for PPP2R1B as a candidate tumor suppressor gene in these cancers. Experimental studies have shown that suppression of PPP2R1B expression enables immortalized human cells to become tumorigenic, and that the wild-type protein forms a complex with the small GTPase RalA. These findings support the role of PPP2R1B as a tumor suppressor involved in regulating RalA function. [10]
A case series described nine cancer patients with germline loss-of-function (LOF) variants in PPP2R1B, with breast cancer being the most frequently observed diagnosis. [11] In all documented cases, individuals also had a family history of cancers including breast, ovarian, prostate, uterine, renal, and colorectal cancer, suggesting that PPP2R1B may function as a predisposition gene in breast and potentially other cancers. [6]
This page is based on this
Wikipedia article Text is available under the
CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.